Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...

The stock's fall snapped a four-day winning streak.

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...

Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...

25 analysts have shared their evaluations of Vertex Pharmaceuticals VRTX during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 in a research note issued to investors on Thursday,Benzinga reports.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday.

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other Renaissance Technologies portfolio’s top stock picks. The American ...